Cargando…
Low-dose rivaroxaban: can cardiovascular events be reduced?
Despite available effective guideline-based preventive therapies, patients with vascular diseases remain at high-risk of recurrent ischaemic events. Novel therapeutic strategies are therefore needed in order to further reduce the residual risk that is present in these high-risk patients. The Cardiov...
Autor principal: | De Luca, Leonardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132608/ https://www.ncbi.nlm.nih.gov/pubmed/37125297 http://dx.doi.org/10.1093/eurheartjsupp/suad034 |
Ejemplares similares
-
Cardiovascular prevention: sometimes dreams can come true
por: Ferrari, Roberto, et al.
Publicado: (2023) -
The PACMAN-AMI trial: a revolution in the treatment of acute coronary syndromes
por: De Luca, Leonardo, et al.
Publicado: (2023) -
The implantable cardiac monitor in heart failure patient: a possible new indication?
por: Cicogna, Francesco, et al.
Publicado: (2023) -
MR guided cardiac ablation: how to build an interventional magnetic resonance suite and what's the role of the imaging
por: Fusco, Armando, et al.
Publicado: (2023) -
Bempedoic acid: what prospective uses?
por: Jacomelli, Ilaria, et al.
Publicado: (2023)